Latest filing published 01 Apr 2022 for NeuBase Therapeutics, Inc., €11k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
William Roland Mann: trading record in brief
This profile gathers the share dealings of William Roland Mann in Ohr Pharmaceutical Inc, where the filings describe the role as chief executive. Over a trading history stretching from 26 April 2021 to 30 March 2022, the count stands at 2 filings.
On the market, this insider has only ever bought: 2 purchases, €31k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2022 alone, the filings show 1 purchase and no sales.
On 1 April 2022 came the latest disclosure, an open-market purchase for €11k in Ohr Pharmaceutical Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to William Roland Mann
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,200 shares@ US$1.92100.0% of flowCommon stockSEC:0001104659-22-041749:0Canonical exit: 28 Jun 2022 (T+90)
1 of 1 declaration